Jan 27 (Reuters) – Pfizer Inc said on Tuesday it agreed to pay $400 million to avert a trial in a class action lawsuit accusing the pharmaceutical giant of misleading investors in connection with off-label marketing.
Pfizer disclosed the agreement-in-principle as it released its fourth-quarter results. The accord, which must be approved by a federal judge in Manhattan, came days ahead of a jury trial set for Feb. 10.
